メディケア・アドバンテージ

Medicare Advantage and Type 2 Diabetes Outcomes: Evaluating Clinical and Social Impacts Amid Rising Costs

By MedXY 08/15/2026

Medicare Advantage (MA) shows no significant improvement over original Medicare (OM) in managing type 2 diabetes outcomes or mitigating related social needs despite higher costs, underscoring the need for effective spending strategies.

Clinical Updates news Oncology Public Health

Quality, Cost, and Timeliness of Cancer Treatment in Medicare Advantage Versus Traditional Medicare: An Evidence-Based Review

By MedXY 07/17/2026

Medicare Advantage beneficiaries with cancer receive guideline-concordant treatment similarly to Traditional Medicare enrollees but at lower costs and comparable timeliness, highlighting implications for healthcare policy and cost-effective oncology care delivery.

news Ophthalmology

Disparities in Access to Intravitreal Anti-VEGF Therapies Among Medicare Advantage Versus Fee-for-Service Beneficiaries

By MedXY 07/05/2026

Medicare Advantage beneficiaries receive fewer higher-cost anti-VEGF injections compared to Fee-for-Service patients, highlighting potential access disparities to newer ophthalmic therapies.

Internal Medicine news Public Health

Medicare Advantage Enforcement Has Been Inconsistent and Financially Modest Despite Expanding Federal Exposure

By MedXY 05/30/2026

A 2010-2023 analysis found that CMS enforcement against Medicare Advantage plans was highly variable, usually limited to modest monetary penalties, and more common among lower-rated contracts serving more socially vulnerable beneficiaries.

Internal Medicine news Public Health

ACP Calls for Stronger Oversight of Medicare Advantage to Protect Patients, Payment Accuracy, and Quality

By MedXY 05/22/2026

The American College of Physicians urges major reforms to Medicare Advantage, including more accurate payment, simpler quality measures, tighter oversight of marketing and prior authorization, and stronger transparency to better protect beneficiaries.